rhuMAb-E25 humanized monoclonal antibody against IgE: Update

The decision to move forward with E25 was based on results of a randomized, double-blind, placebo-controlled Phase II trial in 317 adult and adolescent patients with moderate to severe asthma, which will be presented at the American College of Allergy, Asthma, and Immunology meeting in San Diego in November. GNE said that preliminary results of that trial, which monitored patients over five months, were positive. ...